PDCD1 and colorectal cancer: In a previous study from our center, 29 patients with MSI-H/dMMR locally advanced colorectal cancer received neoadjuvant immunotherapy with a single-agent PD-1 inhibitor, and the ORR was 100% (29/29), consistent with the results of the NICHE study [16, 17].